Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study

Shiu Dong Chung, Sung Shun Weng, Chao Yuan Huang, Herng Ching Lin, Li Ting Kao

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

To date, the relationship between antimuscarinics for overactive bladder (OAB) syndrome and depressive disorder still remains unclear. Therefore, this retrospective cohort study examined the association between antimuscarinic use and the subsequent risk of depressive disorder using a population-based data set. This study used data from the Taiwan Longitudinal Health Insurance Database 2005. We selected 1952 OAB women who received antimuscarinics as the study cohort and 9760 OAB women who did not receive antimuscarinics as the comparison cohort. Each subject was tracked for 3 years from her index date to determine all those who were subsequently diagnosed with depressive disorder. Results indicated that the adjusted hazard ratio (HR) for depressive disorder in OAB women who received antimuscarinics was 1.38 (95% confidence interval [CI], 1.15-1.64) compared with those OAB women who did not receive antimuscarinics. In addition, the adjusted HRs for subsequent depressive disorder for OAB women aged 18-39, 40-59, and ≥60 years who received antimuscarinics were 1.83 (95%CI, 1.27-2.64), 1.36 (95%CI, 1.03-1.81), and 1.16 (95%CI, 0.86-1.56), respectively, compared with those OAB women who did not receive antimuscarinics. We concluded that women with OAB who received antimuscarinics had a significantly higher risk of subsequent depressive disorder compared with those OAB women who did not receive antimuscarinics. Accordingly, clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients.

Original languageEnglish
JournalJournal of Clinical Pharmacology
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Overactive Urinary Bladder
Muscarinic Antagonists
Depressive Disorder
Confidence Intervals
Cohort Studies
Health Insurance
Taiwan
Retrospective Studies
Databases

Keywords

  • Antimuscarinics
  • Depressive disorder
  • Muscarinic receptor antagonist
  • Overactive bladder syndrome

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder : A 3-Year Follow-up Study. / Chung, Shiu Dong; Weng, Sung Shun; Huang, Chao Yuan; Lin, Herng Ching; Kao, Li Ting.

In: Journal of Clinical Pharmacology, 2017.

Research output: Contribution to journalArticle

@article{c77f5aebcdd342d594dcf55e0707f050,
title = "Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study",
abstract = "To date, the relationship between antimuscarinics for overactive bladder (OAB) syndrome and depressive disorder still remains unclear. Therefore, this retrospective cohort study examined the association between antimuscarinic use and the subsequent risk of depressive disorder using a population-based data set. This study used data from the Taiwan Longitudinal Health Insurance Database 2005. We selected 1952 OAB women who received antimuscarinics as the study cohort and 9760 OAB women who did not receive antimuscarinics as the comparison cohort. Each subject was tracked for 3 years from her index date to determine all those who were subsequently diagnosed with depressive disorder. Results indicated that the adjusted hazard ratio (HR) for depressive disorder in OAB women who received antimuscarinics was 1.38 (95{\%} confidence interval [CI], 1.15-1.64) compared with those OAB women who did not receive antimuscarinics. In addition, the adjusted HRs for subsequent depressive disorder for OAB women aged 18-39, 40-59, and ≥60 years who received antimuscarinics were 1.83 (95{\%}CI, 1.27-2.64), 1.36 (95{\%}CI, 1.03-1.81), and 1.16 (95{\%}CI, 0.86-1.56), respectively, compared with those OAB women who did not receive antimuscarinics. We concluded that women with OAB who received antimuscarinics had a significantly higher risk of subsequent depressive disorder compared with those OAB women who did not receive antimuscarinics. Accordingly, clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients.",
keywords = "Antimuscarinics, Depressive disorder, Muscarinic receptor antagonist, Overactive bladder syndrome",
author = "Chung, {Shiu Dong} and Weng, {Sung Shun} and Huang, {Chao Yuan} and Lin, {Herng Ching} and Kao, {Li Ting}",
year = "2017",
doi = "10.1002/jcph.890",
language = "English",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder

T2 - A 3-Year Follow-up Study

AU - Chung, Shiu Dong

AU - Weng, Sung Shun

AU - Huang, Chao Yuan

AU - Lin, Herng Ching

AU - Kao, Li Ting

PY - 2017

Y1 - 2017

N2 - To date, the relationship between antimuscarinics for overactive bladder (OAB) syndrome and depressive disorder still remains unclear. Therefore, this retrospective cohort study examined the association between antimuscarinic use and the subsequent risk of depressive disorder using a population-based data set. This study used data from the Taiwan Longitudinal Health Insurance Database 2005. We selected 1952 OAB women who received antimuscarinics as the study cohort and 9760 OAB women who did not receive antimuscarinics as the comparison cohort. Each subject was tracked for 3 years from her index date to determine all those who were subsequently diagnosed with depressive disorder. Results indicated that the adjusted hazard ratio (HR) for depressive disorder in OAB women who received antimuscarinics was 1.38 (95% confidence interval [CI], 1.15-1.64) compared with those OAB women who did not receive antimuscarinics. In addition, the adjusted HRs for subsequent depressive disorder for OAB women aged 18-39, 40-59, and ≥60 years who received antimuscarinics were 1.83 (95%CI, 1.27-2.64), 1.36 (95%CI, 1.03-1.81), and 1.16 (95%CI, 0.86-1.56), respectively, compared with those OAB women who did not receive antimuscarinics. We concluded that women with OAB who received antimuscarinics had a significantly higher risk of subsequent depressive disorder compared with those OAB women who did not receive antimuscarinics. Accordingly, clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients.

AB - To date, the relationship between antimuscarinics for overactive bladder (OAB) syndrome and depressive disorder still remains unclear. Therefore, this retrospective cohort study examined the association between antimuscarinic use and the subsequent risk of depressive disorder using a population-based data set. This study used data from the Taiwan Longitudinal Health Insurance Database 2005. We selected 1952 OAB women who received antimuscarinics as the study cohort and 9760 OAB women who did not receive antimuscarinics as the comparison cohort. Each subject was tracked for 3 years from her index date to determine all those who were subsequently diagnosed with depressive disorder. Results indicated that the adjusted hazard ratio (HR) for depressive disorder in OAB women who received antimuscarinics was 1.38 (95% confidence interval [CI], 1.15-1.64) compared with those OAB women who did not receive antimuscarinics. In addition, the adjusted HRs for subsequent depressive disorder for OAB women aged 18-39, 40-59, and ≥60 years who received antimuscarinics were 1.83 (95%CI, 1.27-2.64), 1.36 (95%CI, 1.03-1.81), and 1.16 (95%CI, 0.86-1.56), respectively, compared with those OAB women who did not receive antimuscarinics. We concluded that women with OAB who received antimuscarinics had a significantly higher risk of subsequent depressive disorder compared with those OAB women who did not receive antimuscarinics. Accordingly, clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients.

KW - Antimuscarinics

KW - Depressive disorder

KW - Muscarinic receptor antagonist

KW - Overactive bladder syndrome

UR - http://www.scopus.com/inward/record.url?scp=85017280092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017280092&partnerID=8YFLogxK

U2 - 10.1002/jcph.890

DO - 10.1002/jcph.890

M3 - Article

C2 - 28378881

AN - SCOPUS:85017280092

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

ER -